Joao Victor Alessi - Hospital Sirio Libanes

基本信息

Career Trajectory

Bio

I am a dedicated healthcare professional with a profound commitment to advancing our understanding of non-small cell lung cancer (NSCLC) and its treatment. I am both a Thoracic Oncologist and a Clinical Research, specializing in the intricate field of thoracic oncology, where I focus on investigating the mechanisms behind the resistance and response to immune checkpoint inhibitors, a groundbreaking approach in cancer therapy.

Research Interests

Papers共 252 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

MAPK Pathway Activating Alteration and Immunotherapy Efficacy in Squamous Cell Lung Carcinoma: Results from the Randomized, Prospective SQUINT Trial

Federico Cappuzzo,Biagio Ricciuti,Angelo Delmonte,Laura Bonanno, Xiaoyue Wang, Weng Kit Lye, Andreas Görtz,Kalliopi Andrikou,Alessandro Dal Maso,Gabriele Minuti,Maximilian Papi,Joao Victor Alessi,Alessandro Di Federico, Scott Rodig, Mark Magdi Awad,Giulio Metro,Ilaria Attili,Fabiana Vitiello,Sara Pilotto,Stefania Gori, Giulio Rossi,Simonetta Buglioni,Diana Giannarelli,Lorenza Landi

Clinical cancer research an official journal of the American Association for Cancer Researchno. 6 (2025): 1027-1036

Cited0Views0WOSBibtex

Gene Copy Deletion of STK11, KEAP1, and SMARCA4: Clinicopathologic Features and Association with Outcomes to Immunotherapy +/- Chemotherapy in Nonsquamous Non-Small Cell Lung Cancer

Malini M. Gandhi,Arielle Elkrief, Catherine Gutierrez Moore,Biagio Ricciuti,Joao V. Alessi,Allison L. Richards,Sam Tischfield, Jessica Williams,Giuseppe Lamberti,Federica Pecci,Alessandro Di Federico,Maisam Makarem,Bruce E. Johnson,Mizuki Nishino,Lynette M. Sholl,Adam J. Schoenfeld,Mark M. Awad

Journal of Thoracic Oncology (2025)

Cited0Views0WOSBibtex

Determinants of 5-Year Survival in Patients with Advanced NSCLC with PD-L1≥50% Treated with First-Line Pembrolizumab Outside of Clinical Trials: Results from the Pembro-real 5Y Global Registry

Alessio Cortellini,Leonardo Brunetti,Giuseppina Rita Di Fazio,Edoardo Garbo,David J. Pinato,Jarushka Naidoo,Artur Katz, Monica Loza,Joel W. Neal,Carlo Genova,Scott Gettinger,So Yeon Kim,Ritujith Jayakrishnan,Talal El Zarif,Marco Russano,Federica Pecci,Alessandro Di Federico,Mark Awad,Joao Alessi,Michele Montrone,Dwight Hall Owen,Diego Signorelli,Mary Jo Fidler,Mingjia Li,Andrea Camerini,Andrea De Giglio, Lauren Young,Bruno Vincenzi,Giulio Metro,Francesco Passiglia,Sai Yendamuri,Annalisa Guida,Michele Ghidini, Nichola O. Awosika,Andrea Napolitano,Claudia A. M. Fulgenzi,Salvatore Grisanti,Francesco Grossi,Armida D'Incecco,Eleni Josephides, Mieke Van Hemelrijck,Alessandro Russo,Alain Gelibter, Gianpaolo Spinelli,Monica Verrico,Bartlomiej Tomasik,Raffaele Giusti,Thomas Newsom-Davis,Emilio Bria,Martin Sebastian,Maximilian Rost,Martin Forster,Uma Mukherjee,Lorenza Landi,Francesca Mazzoni,Avinash Aujayeb, Manuel Dupont,Alessandra Curioni-Fontecedro,Rita Chiari,Francesco Pantano,Alessandro Morabito,Alessandro Leonetti,Alex Friedlaender,Alfredo Addeo,Federica Zoratto,Michele De Tursi,Luca Cantini,Elisa Roca,Giannis Mountzios,Luigi Della Gravara,Sukumar Kalvapudi,Alessandro Inno,Paolo Bironzo, Rafael Di Marco Barros, David O'Reilly, Jack Bell,Eleni Karapanagiotou,Isabelle Monnet,Javier Baena,Marianna Macerelli,Margarita Majem,Francesco Agustoni,Diego Luigi Cortinovis,Giuseppe Tonini,Gabriele Minuti,Chiara Bennati,Laura Mezquita,Teresa Gorria,Alberto Servetto,Teresa Beninato,Giuseppe Lo Russo,Jacobo Rogado, Laura Moliner,Federica Biello,Frank Aboubakar Nana,Anne-Marie Dingemans,Joachim G. J. Aerts,Roberto Ferrara,Valter Torri,Taher Abu Hejleh,Kazuki Takada,Abdul Rafeh Naqash,Marina Garassino,Solange Peters,Heather Wakelee,Amin H. Nassar,Biagio Ricciuti

JOURNAL FOR IMMUNOTHERAPY OF CANCERno. 2 (2025)

Cited0Views0WOSBibtex

Supplementary Figure 20 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors

crossref（2024）

Cited0Views0Bibtex

Supplementary Table 13 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors

crossref（2024）

Cited0Views0Bibtex

Supplementary Figure 10 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors

crossref（2024）

Cited0Views0Bibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn